Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI

REFERENCES

1. 1.↵
   2. Brat DJ,
   3. Verhaak RG,
   4. Aldape KD, et al

   ; Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481–98 doi:10.1056/NEJMoa1402121 pmid:26061751

   CrossRefPubMed
2. 2.↵
   2. Jenkins RB,
   3. Blair H,
   4. Ballman KV, et al

   . A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852–61 doi:10.1158/0008-5472.CAN-06-1796 pmid:17047046

   Abstract/FREE Full Text
3. 3.↵
   2. Wijnenga MM,
   3. French PJ,
   4. Dubbink HJ, et al

   . The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol 2018;20:103–12 doi:10.1093/neuonc/nox176 pmid:29016833

   CrossRefPubMed
4. 4.↵
   2. Kawaguchi T,
   3. Sonoda Y,
   4. Shibahara I, et al

   . Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol 2016;129:505–14 doi:10.1007/s11060-016-2201-2 pmid:27401154

   CrossRefPubMed
5. 5.↵
   2. Leu K,
   3. Ott GA,
   4. Lai A, et al

   . Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas. J Neurooncol 2017;134:177–88 doi:10.1007/s11060-017-2506-9 pmid:28547590

   CrossRefPubMed
6. 6.↵
   2. Park YW,
   3. Han K,
   4. Ahn SS, et al

   . Whole-tumor histogram and texture analyses of DTI for evaluation of IDH1-mutation and 1p/19q-codeletion status in World Health Organization grade II gliomas. AJNR Am J Neuroradiol 2018;39:693–98 doi:10.3174/ajnr.A5569 pmid:29519794

   Abstract/FREE Full Text
7. 7.↵
   2. Xiong J,
   3. Tan W,
   4. Wen J, et al

   . Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. Eur Radiol 2016;26:1705–15 doi:10.1007/s00330-015-4025-4 pmid:26396108

   CrossRefPubMed
8. 8.↵
   2. Suh CH,
   3. Kim HS,
   4. Jung SC, et al

   . Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis. Eur Radiol 2019;29:745–58 doi:10.1007/s00330-018-5608-7 pmid:30003316

   CrossRefPubMed
9. 9.↵
   2. Beppu T,
   3. Inoue T,
   4. Shibata Y, et al

   . Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas. Surg Neurol 2005;63:56–61; discussion 61 doi:10.1016/j.surneu.2004.02.034 pmid:15639528

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Setsompop K,
    3. Gagoski BA,
    4. Polimeni JR, et al

    . Blipped-controlled aliasing in parallel imaging for simultaneous multislice echo planar imaging with reduced g-factor penalty. Magn Reson Med 2012;67:1210–24 doi:10.1002/mrm.23097 pmid:21858868

    CrossRefPubMed
11. 11.↵
    2. Wu Y,
    3. Zhu Y,
    4. Tang Q, et al

    . Accelerated MR diffusion tensor imaging using distributed compressed sensing. Magn Reson Med 2014;71:763–72 doi:10.1002/mrm.24721 pmid:23494999

    CrossRefPubMed
12. 12.↵
    2. Aliotta E,
    3. Nourzadeh H,
    4. Sanders J, et al

    . Highly accelerated, model-free diffusion tensor MRI reconstruction using neural networks. Med Phys 2019;46:1581–91 doi:10.1002/mp.13400 pmid:30677141

    CrossRefPubMed
13. 13.↵
    2. Capper D,
    3. Weissert S,
    4. Balss J, et al

    . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010;20:245–54 doi:10.1111/j.1750-3639.2009.00352.x pmid:19903171

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Felsberg J,
    3. Wolter M,
    4. Seul H, et al

    . Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 2010;119:501–07 doi:10.1007/s00401-010-0647-4 pmid:20131059

    CrossRefPubMed
15. 15.↵
    2. Riemenschneider MJ,
    3. Jeuken JWM,
    4. Wesseling P, et al

    . Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 2010;120:567–84 doi:10.1007/s00401-010-0736-4 pmid:20714900

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Iglesias JE,
    3. Liu CY,
    4. Thompson P, et al

    . Robust brain extraction across datasets and comparison with publicly available methods. IEEE Trans Med Imaging 2011;30:1617–34 doi:10.1109/TMI.2011.2138152 pmid:21880566

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Kamnitsas K,
    3. Ledig C,
    4. Newcombe VF, et al

    . Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation. Med Image Anal 2017;36:61–78 doi:10.1016/j.media.2016.10.004 pmid:27865153

    CrossRefPubMed
18. 18.↵
    1. Crimi A,
    2. Bakas S,
    3. Kuijf H, et al.

    2. Rathore S,
    3. Bakas S,
    4. Pati S, et al

    . Brain Cancer Imaging Phenomics Toolkit (brain-CaPTk): an interactive platform for quantitative analysis of glioblastoma. In: Crimi A, Bakas S, Kuijf H, et al., eds. Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries. New York: Springer; 2017;10670:133–45 doi:10.1007/978-3-319-75238-9_12

    CrossRef
19. 19.↵
    2. Kingsley PB

    . Introduction to diffusion tensor imaging mathematics, Part III: tensor calculation, noise, simulations, and optimization. Concepts Magn Reson Part A 2006;28A:155–79 doi:10.1002/cmr.a.20050

    CrossRef
20. 20.↵
    2. Vallières M,
    3. Freeman CR,
    4. Skamene SR, et al

    . A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys Med Biol 2015;60:5471–96 doi:10.1088/0031-9155/60/14/5471 pmid:26119045

    CrossRefPubMed
21. 21.↵
    2. Chalkidou A,
    3. O'Doherty MJ,
    4. Marsden PK

    . False discovery rates in PET and CT studies with texture features: a systematic review. PLoS One 2015;10:e0124165 doi:10.1371/journal.pone.0124165 pmid:25938522

    CrossRefPubMed
22. 22.↵
    2. Zhou H,
    3. Vallières M,
    4. Bai HX, et al

    . MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro Oncol 2017;19:862–70 doi:10.1093/neuonc/now256 pmid:28339588

    CrossRefPubMed
23. 23.↵
    2. Xing Z,
    3. Yang X,
    4. She D, et al

    . Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. AJNR Am J Neuroradiol 2017;38:1138–44 doi:10.3174/ajnr.A5171 pmid:28450436

    Abstract/FREE Full Text
24. 24.↵
    2. Lee S,
    3. Choi SH,
    4. Ryoo I, et al

    . Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol 2015;121:141–50 doi:10.1007/s11060-014-1614-z pmid:25205290

    CrossRefPubMed
25. 25.↵
    2. Wasserman JK,
    3. Nicholas G,
    4. Yaworski R, et al

    . Radiological and pathological features associated with IDH1–R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. PLoS One 2015;10:e0123890 doi:10.1371/journal.pone.0123890 pmid:25849605

    CrossRefPubMed
26. 26.↵
    2. Fellah S,
    3. Caudal D,
    4. De Paula AM, et al

    . Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol 2013;34:1326–33 doi:10.3174/ajnr.A3352 pmid:23221948

    Abstract/FREE Full Text
27. 27.↵
    2. Lasocki A,
    3. Tsui A,
    4. Gaillard F, et al

    . Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. J Clin Neurosci 2017;39:170–75 doi:10.1016/j.jocn.2017.01.007 pmid:28214089

    CrossRefPubMed
28. 28.↵
    2. Nakae S,
    3. Murayama K,
    4. Sasaki H, et al

    . Prediction of genetic subgroups in adult supra tentorial gliomas by pre- and intraoperative parameters. J Neurooncol 2017;131:403–12 doi:10.1007/s11060-016-2313-8 pmid:27837434

    CrossRefPubMed
29. 29.↵
    2. Qi S,
    3. Yu L,
    4. Li H, et al

    . Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 2014;7:1895–902 doi:10.3892/ol.2014.2013 pmid:24932255

    CrossRefPubMed
30. 30.↵
    2. Delfanti RL,
    3. Piccioni DE,
    4. Handwerker J, et al

    . Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. J Neurooncol 2017;135:601–09 doi:10.1007/s11060-017-2613-7 pmid:28871469

    CrossRefPubMed
31. 31.↵
    2. Patel SH,
    3. Poisson LM,
    4. Brat DJ, et al

    . T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23:6078–85 doi:10.1158/1078-0432.CCR-17-0560 pmid:28751449

    Abstract/FREE Full Text
32. 32.↵
    2. Broen MP,
    3. Smits M,
    4. Wijnenga MM, et al

    . The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 2018;20:1393–99 doi:10.1093/neuonc/noy048 pmid:29590424

    CrossRefPubMed
33. 33.↵
    2. Saito T,
    3. Muragaki Y,
    4. Maruyama T, et al

    . Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas. Brain Tumor Pathol 2016;33:175–82 doi:10.1007/s10014-016-0249-5 pmid:26849373

    CrossRefPubMed
34. 34.↵
    2. Tan W,
    3. Xiong J,
    4. Huang W, et al

    . Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI. J Magn Reson Imaging 2017;45:492–99 doi:10.1002/jmri.25358 pmid:27367599

    CrossRefPubMed
35. 35.↵
    2. Yamashita K,
    3. Hiwatashi A,
    4. Togao O, et al

    . MR imaging–based analysis of glioblastoma multiforme: estimation of IDH1 mutation status. AJNR Am J Neuroradiol 2016;37:58–65 doi:10.3174/ajnr.A4491 pmid:26405082

    Abstract/FREE Full Text
36. 36.↵
    2. Choi C,
    3. Raisanen JM,
    4. Ganji SK, et al

    . Prospective longitudinal analysis of 2-hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with IDH-mutant glioma. J Clin Oncol 2016;34:4030–39 doi:10.1200/JCO.2016.67.1222 pmid:28248126

    Abstract/FREE Full Text
37. 37.↵
    2. Tietze A,
    3. Choi C,
    4. Mickey B, et al

    . Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. J Neurosurg 2018;128:391–98 doi:10.3171/2016.10.JNS161793 pmid:28298040

    CrossRefPubMed